$ZS

Schlossman Robert sold $1.1M of ZS

Schlossman Robert (Chief Legal Officer) sold 5,394 shares of Zscaler, Inc. (ZS) at $200.00 ($1.08M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schlossman Robert
Published Sep 21, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZS
Neutral
medium confidence
Mentioned
$ZS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZSNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, likely having limited immediate price impact.

02

Market read

Provides a fresh insider transaction record; limited trading relevance.

03

What to watch

10b5-1 plans can be executed irrespective of company performance.

Relevance 5/10Novelty 5/10Timing: 2026-09-21 (filing date)

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$ZSNeutralMedium confidence
Context

Chief Legal Officer Robert Schlossman sold 5,394 Zscaler shares for $1.08M via a 10b5-1 plan on 2026-09-21.

Expected impact

Potential short-term pressure, limited upside impact.

Evidence & confidence

Sale amount is small (~0.2% of holdings) and disclosed via pre‑arranged plan, reducing predictive power.

Market effects

Minimal effect on cybersecurity sector; insider sales are routine.

None

Low

Counterpoint

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

  • Zscaler, Inc.

    Cybersecurity firm listed on NASDAQ under ticker ZS.

  • Robert Schlossman

    Chief Legal Officer of Zscaler.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZSMed

Zscaler (ZS) Sets $8B ARR Goal by FY2031 Amid Mixed Analyst View

Zscaler (ZS) aims to reach $8B in annual recurring revenue by FY2031, a 2.4x increase from current revenue. Analysts' views are mixed, with Morgan Stanley lowering its price target to $185 and UBS raising it to $250. The company's P/S ratio is 10.14x, below its historical median of 18.9x, reflecting market skepticism about growth and profitability.

$ZSMed

ZSCALER (ZS) Maintained by JP Morgan -- Price Target Raised to $

JP Morgan maintained an Overweight rating on Zscaler (ZS) and raised its price target from $215 to $245. The company's GF Value™ suggests it is 28.2% undervalued, with a GF Score™ of 76/100. Insider selling totaled $6.4M over the past three months. Zscaler operates in cloud-native cybersecurity, serving large enterprises and government agencies.

$ZSMed

ZS Maintained by Barclays -- Price Target Raised to $225

Barclays maintained an Overweight rating for Zscaler (ZS) and raised its price target to $225 from $220. GuruFocus values ZS at $296.22, suggesting a 29.1% undervaluation at its current price of $210.08. The company has a GF Score of 76/100, indicating strong growth and valuation but low profitability. Insider selling totaled $6.4M in the last 3 months.